With patent losses on the horizon, Amgen refocuses its business strategy

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

By Alexandra Pecci • March 5, 2025

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

By Jonathan Gardner • March 5, 2025

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Americans want to participate in clinical trials — so why don’t they?

A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

By Kelly Bilodeau • March 4, 2025

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

By Michael Gibney • March 4, 2025

Teva targets schizophrenia to build on innovative medicines growth

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

By Meagan Parrish • Feb. 28, 2025

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

By Michael Gibney • Feb. 27, 2025

Cancer vaccines have stumbled, but the approach is gaining new steam

The number of candidates in development has nearly doubled over the past 15 years.

By Kelly Bilodeau • Feb. 26, 2025

Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

By Alexandra Pecci • Feb. 25, 2025

Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

By Michael Gibney • Feb. 25, 2025

Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production

The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.

By Alexandra Pecci • Feb. 19, 2025

CRISPR’s cardio catch-all drives a biotech’s broad potential

Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

By Kelly Bilodeau • Feb. 18, 2025

In the crowded cardio space, it’s David vs. Goliath for small biotechs

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

By Alexandra Pecci • Feb. 11, 2025

Are orexins the next golden child of neuroscience?

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

By Meagan Parrish • Feb. 10, 2025

Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

By Amy Baxter • Feb. 10, 2025

As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D

With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.

By Alexandra Pecci • Feb. 5, 2025

What should pharma make of the FDA going dark on DEI?

After a series of potent executive orders last week, the FDA removed draft guidance on diversity in clinical trials.

By Meagan Parrish • Feb. 4, 2025

Drugmakers prep for bird flu outbreak, despite continued low risk

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.

By Kelly Bilodeau • Feb. 3, 2025

A new, non-opioid pain drug is here. Getting it to patients could be agony.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?

By Jacob Bell • Feb. 3, 2025

Pharma’s forecast for 2025: Sowing seeds of a rebound

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

By Meagan Parrish • Jan. 31, 2025

Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge

NIH grants that help fund drug development were caught in the mix of confusing executive orders this week.

By Amy Baxter • Jan. 31, 2025

A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?

Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

By Amy Baxter • Updated Feb. 4, 2025

Natural killer cells, a rising alternative to CAR-T cell therapy

These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.

By Kelly Bilodeau • Jan. 27, 2025

Gene therapies have been uneven for DMD — but these companies hope to turn the tide

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

By Meagan Parrish • Jan. 24, 2025

J&J is all in on tau-targeted Alzheimer’s candidates. Will the approach lead to more effective treatments?

Anti-tau candidates haven’t crossed the regulatory threshold like their anti-amyloid counterparts, but J&J’s clinical efforts could lead in the right direction.

By Michael Gibney • Jan. 23, 2025

After an obesity stumble, BioAge reconnects with its longevity pipeline

The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.

By Alexandra Pecci • Jan. 22, 2025